Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project

被引:15
作者
Hallert, E. [1 ,2 ]
Husberg, M. [1 ]
Kalkan, A. [1 ]
Skogh, T. [3 ]
Bernfort, L. [1 ]
机构
[1] Linkoping Univ, Ctr Med Technol Assessment, Dept Med & Hlth Sci, Fac Hlth Sci, SE-58183 Linkoping, Sweden
[2] Linkoping Univ Hosp, Dept Cardiovasc Dis & Special Med, Linkoping, Sweden
[3] Linkoping Univ Hosp, Fac Hlth Sci, Dept Clin & Expt Med, AIR Rheumatol Unit, Linkoping, Sweden
基金
瑞典研究理事会;
关键词
ANTITUMOR NECROSIS FACTOR; CONVENTIONAL COMBINATION TREATMENT; WORK DISABILITY; FOLLOW-UP; DISEASE-ACTIVITY; RA; QUESTIONNAIRE; ILLNESS; SWEDEN; TRIAL;
D O I
10.3109/03009742.2013.835442
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To calculate total costs over 6 years after diagnosis of early rheumatoid arthritis (RA). Method: In the longitudinal prospective multicentre TIRA study, 239 patients from seven units, diagnosed in 1996-98, reported regularly on health-care utilization and the number of days lost from work. Costs were obtained from official databases and calculated using unit costs (Swedish kronor, SEK) from 2001. Indirect costs were calculated using the human capital approach (HCA). Costs were inflation adjusted to Euro June 2012, using the Swedish Consumer Price Index and the exchange rate of June 2012. Statistical analyses were based on linear mixed models (LMMs) for changes over time. Results: The mean total cost per patient was EUR 14 768 in year 1, increasing to EUR 18 438 in year 6. Outpatient visits and hospitalization decreased but costs for surgery increased from EUR 92/patient in year 1 to EUR 444/patient in year 6. Drug costs increased from EUR 429/patient to EUR 2214/patient, mainly because of the introduction of biologics. In year 1, drugs made up for 10% of direct costs, and increased to 49% in year 6. Sick leave decreased during the first years but disability pensions increased, resulting in unchanged indirect costs. Over the following years, disability pensions increased further and indirect costs increased from EUR 10 284 in year 1 to EUR 13 874 in year 6. LMM analyses showed that indirect costs were unchanged whereas direct costs, after an initial fall, increased over the following years, leading to increasing total costs. Conclusions: In the 6 years after diagnosis of early RA, drug costs were partially offset by decreasing outpatient visits but indirect costs remained unchanged and total costs increased.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 35 条
[1]   Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: The jury is still out [J].
Allaire, Saralynn ;
Wolfe, Frederick ;
Niu, Jingbo ;
Zhang, Yuqing ;
Zhang, Bin ;
LaValley, Michael .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (08) :1082-1089
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]   Effect of the Early Use of the Anti-Tumor Necrosis Factor Adalimumab on the Prevention of Job Loss in Patients With Early Rheumatoid Arthritis [J].
Bejarano, Victoria ;
Quinn, Mark ;
Conaghan, Philip G. ;
Reece, Richard ;
Keenan, Anne-Maree ;
Walker, David ;
Gough, Andrew ;
Green, Michael ;
McGonagle, Dennis ;
Adebajo, Ade ;
Jarrett, Stephen ;
Doherty, Sheelagh ;
Hordon, Lesley ;
Melsom, Richard ;
Unnebrink, Kristina ;
Kupper, Hartmut ;
Emery, Paul .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (10) :1467-1474
[4]   Understanding emerging treatment paradigms in rheumatoid arthritis [J].
Breedveld, Ferdinand C. ;
Combe, Bernard .
ARTHRITIS RESEARCH & THERAPY, 2011, 13
[5]  
Burmeister GD, 2012, NATURE REV RHEUMATOL, V8, P65
[6]   Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US [J].
Chung, C. P. ;
Sokka, T. ;
Arbogast, P. G. ;
Pincus, T. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) :1653-1657
[7]   ASSESSING DISABILITY IN PATIENTS WITH RHEUMATOID-ARTHRITIS - USE OF A SWEDISH VERSION OF THE STANFORD HEALTH ASSESSMENT QUESTIONNAIRE [J].
EKDAHL, C ;
EBERHARDT, K ;
ANDERSSON, SI ;
SVENSSON, B .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1988, 17 (04) :263-271
[8]   Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study [J].
Emery, Paul ;
Kvien, Tore K. ;
Combe, Bernard ;
Freundlich, Bruce ;
Robertson, Deborah ;
Ferdousi, Tahmina ;
Bananis, Eustratios ;
Pedersen, Ronald ;
Koenig, Andrew S. .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (06) :989-992
[9]   Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial [J].
Eriksson, Jonas K. ;
Neovius, Martin ;
Bratt, Johan ;
Petersson, Ingemar F. ;
van Vollenhoven, Ronald F. ;
Geborek, Pierre ;
Ernestam, Sofia .
JAMA INTERNAL MEDICINE, 2013, 173 (15) :1407-1414
[10]  
Franke LC, 2009, CLIN EXP RHEUMATOL, V27, pS118